NCT04791839

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Since anti-PD1, anti-TIGIT, and A2R antagonists have complementary mechanisms of action, and the latter two have shown synergism in combination with antibodies against PD-1, othis study aims to evaluate the efficacy and tolerability of the triplet combination of zimberelimab, domvanalimab, and etrumadenant in patients with non-small cell lung cancer previously treated with immune checkpoint blockade therapy.

Conditions

• Non Small Cell Lung Cancer
• Non-small Cell Carcinoma
• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Zimberelimab	Zimberelimab will be supplied by Arcus Biosciences.
DRUG	Domvanalimab	Domvanalimab will be supplied by Arcus Biosciences.
DRUG	Etrumadenant	Etrumadenant will be supplied by Arcus Biosciences.

Timeline

• Start date: 2021-08-04
• Primary completion: 2026-04-30
• Completion: 2030-06-30
• First posted: 2021-03-10
• Last updated: 2025-11-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study